The postponed ACIP meeting comes barely a week after Robert F. Kennedy, Jr. was confirmed as Secretary of Health and Human ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Various respiratory illnesses as well as the Norovirus, otherwise known as the stomach flu, are circulating in the Chippewa Valley. “We’ve seen an increase in COVID-19, RSV, influenza, as well as ...

State health officials are seeing the highest numbers all winter lately with approximately 9.5 of the 600 tests for RSV ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

GSK's vaccine has just hit the mark in a phase ... It is also being developed for use in pregnant women to prevent RSV in newborns, an indication for which it looks to be in the lead after GSK ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.